Comment from Truveta Inc.

Summary: Truveta Inc. is submitting a response to the FDA's Request for Information regarding the AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program. The company argues that its HIPAA-compliant AI infrastructure can improve trial speed, quality, and patient recruitment by providing real-time data normalization and automated patient identification.